Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

HboFam May. 28 at 5:56 AM

$SLS $ABBV $IBRX Angelos ”recent multi-center study evaluating real-world practice data for the highly active alternating regimen pioneered at MD Anderson Cancer Center (Kadia et al.) in older, high-risk Acute Myeloid Leukemia (AML) patients reveals a profound paradox in modern oncology: - High-intensity innovation works in community settings. 63% of untreated elderly patients (median age 74) achieved a composite complete remission (CRc). Modern triplets are successfully expanding the pool of patients achieving CR1 and CR2. - Despite being touted as a "bridge to transplant," only 15% of these patients actually made it to an allogeneic stem cell transplant. For the remaining 85% who are too frail or older, a steep "therapeutic cliff" remains. Without a transplant, their median overall survival was just 8 months, cut short by cumulative toxicities and eventual resistance to continuous chemotherapy backbones.”

0 · Reply

55X_ROI_Q1_2026 May. 28 at 1:21 AM

$SLS $ABBV $IBRX

1 · Reply

55X_ROI_Q1_2026 May. 27 at 11:22 PM

$SLS $ABBV $IBRX 3 Dr/s Who Treat Actual Phase 3 Trial patients: " Survival on BAT is dismal, just 6-8 months" "extremely poor on the order of 5-7 months" " I Strongly believe Gps will reach the primary endpoint "/

3 · Reply

55X_ROI_Q1_2026 May. 27 at 10:51 PM

$SLS market value increased 1,200% since the IDMC UNBLINDED ACTUAL PHASE 3 MOS AND IR DATA from the Interim Analysis Actual Phase 3 Survival and Immune Response Data - that TOLD Smart Money Paying Attention - GPS is 100% For Sure Golden. - 167 Institutional Funds Invested - Up from Just 39 While We are seeing near MIRACULOUS Extended Survival Among ALL POOLED P3 Patients in the REGAL trial for SECOND REMISSION MAINTENANCE (CR2) - Aza+VEN / BAT Best Available Treatment for Control Arm Patients Recently FAILED 3 Large Phase 3 Trials conducted by $ABBV VIALE-M - AML First Remission Maintenance Trial FAILED VIALE-T - AML Post Transplant Maintenance Trial FAILED VERONA - MDS/High Risk AML Precursor Trial FAILED. $IBRX is DEAD MONEY vs What SLS will Be Doing. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml

0 · Reply

Mike22332233 May. 27 at 9:52 PM

$SLS From here, $SLS could return an additional 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing !!! ... the opening BO Offer will be placed at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... This is the largest position in an almost $1.4 mil portfolio … Again, this is the single best asymmetrical investment I have found in over 40 years of investing !!!! ... The play here is simple …. Buy as much as you can after doing your DD … HOLD until BO (ignore everything from now till BO) !!!! … AND after first offer is made … Look for a bidding war !!!!! … Best of luck to all !!! … And, remember to PLEASE always give back something to medical research ... If you agree ...... LIKE & FOLLOW me 👉 @Mike22332233 for all latest info and DD -- and maybe find THE NEXT SLS !!!

3 · Reply

Loudermilk64 May. 27 at 9:00 PM

$ABBV this stock always loses. What gains are they talking about?

0 · Reply

StocktwitsNews May. 27 at 8:26 PM

ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug $ABBV https://stocktwits.com/news/equity/markets/abbv-stock-gains-on-winning-fda-approval-for-rare-blood-cancer-drug/cZggZYAReru

0 · Reply

SwingTraderPro1 May. 27 at 8:08 PM

BREAKING: $ABBV just secured FDA approval for pivekimab sunirine-PVZY targeting blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and highly aggressive blood cancer. This is not just another label expansion,this is AbbVie deepening its footprint in ultra-orphan hematology, where pricing power and unmet need are both extreme. Traders should note: rare disease approvals often translate into high-margin, low-competition revenue streams over time. Long-term pipeline strength just got another boost. Watch how the market digests this—biotech catalysts like this can quietly re-rate big pharma over time. $ABBV in play.

0 · Reply

GreenEnergy7B May. 27 at 8:00 PM

$ALT Approx 10% better placebo adj, 3x faster, and 0 disc, better Tolerability profile vs Wegovy. 1.2mg dose looks very attractive $LLY $RHHBY $SNY $ABBV

1 · Reply

55X_ROI_Q1_2026 May. 27 at 7:07 PM

$SLS $ABBV - this $8 Stock Will Be an $80 Stock Phase 3 Registrational Results are Coming.

0 · Reply

AbbVie announces FDA approval of DECNUPAZ

ABBV

May 27, 2026, 6:18 PM EDT - 11 hours ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

ABBV

May 27, 2026, 3:33 PM EDT - 14 hours ago

US FDA approves AbbVie's rare blood cancer drug

ABBV

2026-05-27T19:25:11.000Z - 14 hours ago

FDA approves AbbVie’s Decnupaz for blastic plasmacytoid dendritic cell neoplasm

ABBV

2026-05-22T12:12:15.000Z - 5 days ago

AbbVie reports positive CHMP opinion for Maviret

ABBV

May 22, 2026, 8:00 AM EDT - 5 days ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

ABBV

May 21, 2026, 6:46 PM EDT - 6 days ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

ABBV

2026-05-21T20:19:37.000Z - 6 days ago

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

ABBV

May 21, 2026, 4:10 PM EDT - 6 days ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

ABBV

2026-05-15T12:51:42.000Z - 12 days ago

AbbVie price target lowered to $235 from $236 at Evercore ISI

ABBV

2026-05-14T11:07:12.000Z - 13 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

ABBV

May 13, 2026, 2:20 PM EDT - 14 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 9, 2026, 10:08 AM EDT - 18 days ago

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

ABBV

May 8, 2026, 10:00 AM EDT - 19 days ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 21 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

ABBV

2026-05-05T12:32:52.000Z - 22 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

ABBV

May 5, 2026, 8:05 AM EDT - 22 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

ABBV IBD

2026-05-04T12:13:35.000Z - 23 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

ABBV

May 2, 2026, 8:45 AM EDT - 25 days ago

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

ABBV AZN GSK

May 1, 2026, 3:05 PM EDT - 26 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

ABBV

May 1, 2026, 10:03 AM EDT - 26 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

ABBV BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 27 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

ABBV

2026-04-30T18:00:46.000Z - 27 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

ABBV

2026-04-30T13:31:03.000Z - 27 days ago

AbbVie price target raised to $265 from $262 at Canaccord

ABBV

Apr 30, 2026, 9:00 AM EDT - 27 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

ABBV

2026-04-30T10:15:57.000Z - 27 days ago

AbbVie upgraded to Buy at BofA on durable growth

ABBV

2026-04-30T10:14:18.000Z - 27 days ago

AbbVie upgraded to Buy from Neutral at BofA

ABBV

Apr 29, 2026, 2:50 PM EDT - 4 weeks ago

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

ABBV

2026-04-29T16:41:09.000Z - 4 weeks ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

ABBV

2026-04-29T16:39:58.000Z - 4 weeks ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

ABBV

2026-04-29T16:39:07.000Z - 4 weeks ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

ABBV

2026-04-29T13:25:07.000Z - 4 weeks ago

AbbVie says ‘especially pleased’ with immunology and neuroscience results

ABBV

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 4 weeks ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

ABBV

Apr 29, 2026, 7:50 AM EDT - 4 weeks ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

ABBV

Apr 29, 2026, 7:47 AM EDT - 4 weeks ago

AbbVie Reports First-Quarter 2026 Financial Results

ABBV

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

ABBV

Apr 28, 2026, 7:00 AM EDT - 4 weeks ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

ABBV

Apr 27, 2026, 8:05 AM EDT - 4 weeks ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

ABBV

Apr 23, 2026, 4:19 PM EDT - 4 weeks ago

US FDA declines to approve AbbVie's wrinkle treatment

ABBV

Apr 23, 2026, 4:05 PM EDT - 4 weeks ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

ABBV

Apr 22, 2026, 12:59 PM EDT - 5 weeks ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

ABBV

Apr 22, 2026, 12:02 PM EDT - 5 weeks ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

ABBV

Apr 20, 2026, 2:30 AM EDT - 5 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

ABBV

Apr 14, 2026, 8:50 AM EDT - 6 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

ABBV

Apr 13, 2026, 2:24 AM EDT - 6 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

ABBV

Apr 12, 2026, 7:15 AM EDT - 6 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

ABBV

Apr 9, 2026, 2:00 PM EDT - 6 weeks ago

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

ABBV AMCR CVX

Apr 8, 2026, 1:38 PM EDT - 7 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

ABBV

Apr 8, 2026, 8:00 AM EDT - 7 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

ABBV

Apr 7, 2026, 9:53 AM EDT - 7 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

ABBV

Apr 7, 2026, 9:00 AM EDT - 7 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

ABBV

Apr 3, 2026, 11:08 AM EDT - 7 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AMGN AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 7 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO ABBV AMGN BMY MRK

Apr 2, 2026, 5:33 PM EDT - 7 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AMGN AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 7 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO ABBV AMGN BMY MRK

Apr 2, 2026, 2:59 PM EDT - 7 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AMGN AZN BMY MRK

Mar 31, 2026, 8:05 AM EDT - 2 months ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

ABBV

Mar 31, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

ABBV

Mar 27, 2026, 10:00 AM EDT - 2 months ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

ABBV

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

ABBV

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

ABBV AMRX NVS OGN

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

ABBV

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

ABBV

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

ABBV AZN NVS SNY

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

ABBV

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

ABBV

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy Filing

Mar 6, 2026, 8:26 AM EST - 2 months ago

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

ABBV GILD V

HboFam May. 28 at 5:56 AM

0 · Reply

55X_ROI_Q1_2026 May. 28 at 1:21 AM

$SLS $ABBV $IBRX

1 · Reply

55X_ROI_Q1_2026 May. 27 at 11:22 PM

3 · Reply

55X_ROI_Q1_2026 May. 27 at 10:51 PM

0 · Reply

Mike22332233 May. 27 at 9:52 PM

3 · Reply

Loudermilk64 May. 27 at 9:00 PM

$ABBV this stock always loses. What gains are they talking about?

0 · Reply

StocktwitsNews May. 27 at 8:26 PM

ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug $ABBV https://stocktwits.com/news/equity/markets/abbv-stock-gains-on-winning-fda-approval-for-rare-blood-cancer-drug/cZggZYAReru

0 · Reply

SwingTraderPro1 May. 27 at 8:08 PM

0 · Reply

GreenEnergy7B May. 27 at 8:00 PM

$ALT Approx 10% better placebo adj, 3x faster, and 0 disc, better Tolerability profile vs Wegovy. 1.2mg dose looks very attractive $LLY $RHHBY $SNY $ABBV

1 · Reply

55X_ROI_Q1_2026 May. 27 at 7:07 PM

$SLS $ABBV - this $8 Stock Will Be an $80 Stock Phase 3 Registrational Results are Coming.

0 · Reply

55X_ROI_Q1_2026 May. 27 at 6:59 PM

$SLS $ABBV 6 events in the last 4.5 months 1 event every 3 weeks Not that events are linear, this far along an OS curve - 26 months ranging up to 64 months - could see 2 events in single week. - Already been 2.5 weeks since the 78th... The Share Price will continue climbing until the 80th EVENT PR - and then it LAUNCHES.

0 · Reply

jcooptechit May. 27 at 5:18 PM

$CUE | SMALL-CAP BIOTECH SETUP WITH BIG RE-RATE ENERGY NASDAQ-listed, fresh $30M private placement, Phase 2 exposure with CUE-221, and Big Pharma validation through Boehringer Ingelheim. Key Levels: ✅ Reaccumulation: $18.29–$22.30 ✅ Breakout: $25.56 ✅ Major resistance: $30.74–$33.08 ✅ Target: $41.35+ As long as CUE holds this reaccumulation zone, the structure stays constructive. A move over $25.56 could bring momentum back fast and clearing $33.08 puts $41.35+ in play. Small-cap biotech can move quick when capital, catalysts, and technicals line up. 🔥 Communicated - Disclaimer: https://stockresearchtoday.com/cue/ Sector Peers: $LLY $JNJ $MRK $ABBV

0 · Reply

55X_ROI_Q1_2026 May. 27 at 4:51 PM

$IMGN $SLS Be Holding when the 80th EVENT PR is ANNOUNCED. Expect a 2x 3x+ Move and the share Price will continue CLIMBING. Gps is truly worth Several Tens of billions to big Pharma. -- discussion regarding GPS WT1 Value -- Gps + Pembro/Keytruda Phase 2 Trial Results - achieved Longer Survival for PR/ROC Patients than Elahere/ $IMGN which $ABBV bought for $10.1B Elahere MOS of 16.46 MONTHS / GPS Key 18.4 MONTHS. - Just this 1 Direct Market Comp at $10B GPS is worth Tens of Billions to big Pharma. Even the $MRK Dr. co-authoring the Final P2 DATA, stated Gps warranted further P3 Trials, - this is a massively bullish in Medspeak.

0 · Reply

55X_ROI_Q1_2026 May. 27 at 2:59 PM

$SLS 2 Points: BAT / for control ARM Patients FAILED 3 Large Phase 3 Trials conducted by $ABBV - this $8 Stock Will Be an $80 Stock GPS Phase 3 MOS > 30 Months for CR2/3 Patients is better than the 26/7 Month MOS for Onureg in CR1. - once we get the 80th Event PR - Institutional Funds will be Running all the Numbers - What is GPS WORTH.?. This $8 Stock will be an $80 Stock and Climbing - MARK THIS POST GPS Phase 3 MOS > 30 Months Requires the Market Factor Additional Massive Value for GPS in CR1.

0 · Reply

Loudermilk64 May. 27 at 2:59 PM

$ABBV Buy the dip down around here then?

0 · Reply

Mike22332233 May. 27 at 1:56 PM

$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! .. From here, SLS could return 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing !!! ... ALSO, this week I expect the twice delayed TO for $LSTA at $5.00 plus a CVR for another future possible $1.00, to move forward, and from current $3.14 price, to give me a +59% return ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I post my Special Situation Stocks that have potential for FAST & HUGE profits ... which I always plow back into more $SLS !!!

1 · Reply

55X_ROI_Q1_2026 May. 27 at 5:10 AM

$SLS $ABBV $ABVX When the 80th EVENT is Announced, this is some of the Revenue Institutional Investors and Big Pharma is Looking at.

0 · Reply

55X_ROI_Q1_2026 May. 27 at 3:19 AM

$SLS $ABBV While we are seeing Near Miraculous Survival in ALL POOLED REGAL PHASE 3 Patients, AZA+Ven, the Best Available Treatment / BAT for Control Arm Patients in the REGAL Trial, recently Failed 3 Large Phase 3 Trials. - including Failing the VIALE-M - Phase 3 Maintenance Trial for AML patients in First Remission (CR1). https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=results $ABBV Terminated the Trial at 116 Patients, and didn't make it out of the Safety Phase - they tried 7 different Dosing Schedules, all Oral IV Subq --- Aza+VEN Failed as a Maintenance treatment in CR1 - it is failed is the AML CR2 REGAL Control Arm. Aza+VEN als FAILED the VIALE-T - Post Transplant Maintenance Phase 3. IT IS NOT COMPLICATED...

0 · Reply

semiguy May. 26 at 10:31 PM

$PH $A $ABBV $FAI.X I told you last week - Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe 2026 SYMBOL(MX) Magnachip a small cap power solutions semiconductor company based in South Korea. • MKT Cap of $230 million. • Revenue of $180 million. • 8 inch foundry worth approximately 200 million – 36K wafers a month • Cash of $50 million, trading at $5.70 a share. ( as of last Friday) • Won’t be at this price for long. Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe https://www.businesswire.com/news/home/20260526332549/en/Magnachip-to-Showcase-MV-MOSFET-Portfolio-for-AI-Servers-and-Data-Centers-Alongside-Its-Broader-Power-Semiconductor-Portfolio-at-PCIM-Europe-2026

0 · Reply

55X_ROI_Q1_2026 May. 26 at 7:54 PM

$SLS Smarter Money than Us is buying Every Cheap Share Idiots will Sell. - it is not complicated, while we await and are seeing Near Miraculous All Pooled Survival, BAT for CONTROL ARM Patients - AZA +VEN - Recently Failed 3 Large Phase 3 Trials conducted by $ABBV go look "WITH RESULTS"

0 · Reply

MarketBeat May. 26 at 4:01 PM

https://marketbeat.com/a/8675686/ $ABBV 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade

0 · Reply

Loudermilk64 May. 26 at 3:53 PM

$ABBV depreasing…

0 · Reply

Market Cap	376.54B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	21.17
Forward PE	15.08
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	4,640,400
Avg Vol	6,729,662
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	63%
Beta	0.32
Analysts	Strong Sell
Price Target	$250.90